Financial Gravity Asset Management, Inc. Mirati Therapeutics, Inc. Transaction History

Financial Gravity Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jun 26, 2024	BUY	$41.99 - $62.38 $0 - $0	0 New	0 $9,000
Q4 2023 Feb 15, 2024	BUY	$41.99 - $62.38 $0 - $0	0 New	0 $0
Q3 2023 Nov 15, 2023	SELL	$27.8 - $45.35 $1,000 - $1,632	-36 Closed	0 $0
Q2 2023 Aug 08, 2023	SELL	$36.13 - $49.49 $36 - $49	-1 Reduced 2.7%	36 $10,000
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $292 - $434	-8 Reduced 17.78%	37 $6,000
Q4 2022 Feb 15, 2023	SELL	$41.27 - $98.62 $6,809 - $16,272	-165 Reduced 78.57%	45 $12,000
Q3 2022 Nov 03, 2022	BUY	$59.5 - $86.7 $12,495 - $18,207	210 New	210 $10,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.